Clinical Trials Logo

Nonalcoholic Steatohepatitis clinical trials

View clinical trials related to Nonalcoholic Steatohepatitis.

Filter by:

NCT ID: NCT04389775 Completed - Obesity Clinical Trials

To Evaluate the Safety, Tolerability, PK, and PD of XW003 Injection in Healthy Adult Participants

XW003
Start date: March 29, 2020
Phase: Phase 1
Study type: Interventional

XW003 is an acylated human GLP-1 analogue and is being development for diabetes mellitus, obesity and nonalcoholic steatohepatitis (NASH) management. This is a first-in-human (FIH), single-centre, double blind, randomised, SAD and MAD study of XW003 conducted in healthy adult participants. The study is designed to evaluate the safety, tolerability, PK, and PD of XW003 in healthy adult participants.

NCT ID: NCT04389593 Recruiting - Clinical trials for Nonalcoholic Steatohepatitis

Comparative and Additive Diagnostic Performance of Magnetic Resonance Elastography (MRE) and Corrected-T1 (cT1) for Fibrosis and Inflammation in Nonalcoholic Steatohepatitis (NASH) Using Histology as Reference

Start date: May 21, 2019
Phase:
Study type: Observational

This pilot study will evaluate conventional and investigational MR imaging and spectroscopic sequences and collect data to help plan more definitive future studies.

NCT ID: NCT04342793 Completed - Clinical trials for Nonalcoholic Steatohepatitis

A Study to Evaluate the Efficacy and Safety of ALS-L1023 in Subjects With NASH

Start date: December 4, 2019
Phase: Phase 2
Study type: Interventional

The main objective of this study is to evaluate safety and efficacy of ALS-L1023 in patients with Non-alcoholic steatohepatitis

NCT ID: NCT04235205 Completed - Clinical trials for Nonalcoholic Steatohepatitis

Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease

Start date: January 29, 2020
Phase: Phase 2
Study type: Interventional

The objective is to evaluate the efficacy and safety of once-daily oral doses of 10 mg elobixibat in combination with 9g cholestyramine powder (cholestyramine 4g) in patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).

NCT ID: NCT04216693 Withdrawn - Clinical trials for Nonalcoholic Steatohepatitis

Digoxin for Patients With Non-alcoholic Steatohepatitis (NASH)

Start date: June 1, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess if digoxin is safe and efficacious in treating patients with non-alcoholic steatohepatitis (NASH) within the approved target range of 0.7 to 1 ng/ml.

NCT ID: NCT04210245 Completed - Clinical trials for Nonalcoholic Steatohepatitis

Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)

Start date: March 23, 2020
Phase: Phase 2
Study type: Interventional

A multi-center evaluation of aldafermin in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis.

NCT ID: NCT04166773 Completed - Clinical trials for Nonalcoholic Steatohepatitis

A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)

SYNERGY-NASH
Start date: November 19, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to see if the study drug, tirzepatide administered once weekly, is safe and effective as a treatment for Nonalcoholic Steatohepatitis (NASH).

NCT ID: NCT04152473 Completed - Clinical trials for Nonalcoholic Steatohepatitis

Safety and Tolerability of Oral Proglumide for NASH

STOPNASH
Start date: December 13, 2019
Phase: Phase 1
Study type: Interventional

This study is an open labelled Phase I/II clinical trial, designed to evaluate the safety and efficacy of an oral cholecystokinin (CCK) receptor antagonist, proglumide, at escalating doses in subjects with NASH. An extended use protocol has been approved for subjects completing this study that show benefit or are at risk of Liver disease progression to continue on Proglumide at 1200 mg / day for an additional 3-9 months. Subjects in the extended protocol will have telephone visits monthly and in the research unit every 3 months for safety lab tests and research blood for fibrosis analysis.

NCT ID: NCT04147195 Terminated - Clinical trials for Non-alcoholic Fatty Liver Disease

Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH)

NEXSCOT
Start date: June 4, 2020
Phase: Phase 2
Study type: Interventional

This clinical study was designed to evaluate the safety, tolerability, pharmacokinetics and efficacy of various single and combination treatments in adult patients with non-alcoholic fatty liver disease (NAFLD) who manifest a non-alcoholic steatohepatitis (NASH)-like biomarker phenotype.

NCT ID: NCT04137055 Completed - Clinical trials for Nonalcoholic Steatohepatitis

Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP0678, and the Effect of Food on ZSP0678 Pharmacokinetics

Start date: November 19, 2019
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety, tolerability and pharmacokinetics (PK) of escalating single-and multiple-oral doses of ZSP0678 on fasted condition, and characterize PK of ZSP0678 on an empty stomach (fasted condition) and following a high fat, high calorie meal (fed condition) in a 2-period, 2-sequence manner. The study will be conducted in 3 parts (Ascending single dose, multiple dose and food effect). Participants will receive either ZSP0678 or placebo .